The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Sigvotatug vedotin

Geo Regions

Sigvotatug vedotin

Sigvotatug vedotin (SGN-B6A) is an investigational compound. Its safety and efficacy have not been established

Overview + Rationale

  • Sigvotatug vedotin (SGN-B6A) is an investigational antibody-drug conjugate composed of 3 components: a monoclonal antibody directed to IB6 (integrin beta-6), a microtubule-disrupting agent MMAE (monomethyl auristatin E), and a protease-cleavable mc-vc (maleimidocaproyl-valine citrulline) linker that covalently attaches MMAE to the antibody, which enables preferential release of MMAE within target cells1 
  • IB6 is a cell surface receptor that promotes cellular adhesion through interactions with the extracellular matrix, which plays a major role in solid tumor pathogenesis and invasiveness2,3 
  • IB6 expression is normally low but is highly upregulated during pathogenesis4-6 
  • IB6 is expressed in numerous solid tumors including non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal cancer, and cutaneous squamous cell carcinoma1,7-9 
  • IB6 is a proposed negative prognostic marker based on multiple analyses9,10

Mechanism of Action

Sigvotatug vedotin (SGN-B6A) is thought to induce tumor cell death through: 

• Preferential release of monomethyl auristatin E within target cells and subsequent apoptosis1 

• Bystander effect11 

• Induction of immunogenic cell death12,13

Stage of Development

small icon for other/multiple cancer
Advanced Solid Tumors
Phase 1 Monotherapy
Small icon representing Lung Thoracic Cancer
Non-Small Cell Lung Cancer (NSCLC)
Phase 3 Monotherapy

REFERENCES: 1. Lyon RP. [published online ahead of print, 2023 Aug 25]. Mol Cancer Ther. 2023;MCT-22-0817; 2. Harisi R. Onco Targets Ther. 2015: 1387-98; 3. Niu J. Cancer Lett. 2017;403: 128-37; 4. Desgrosellier JS. Nat Rev Cancer. 2010;10:9-22; 5. Bandyopadhyay A. Curr Drug Targets. 2009.10:645-52; 6. Brzozowska E and Deshmukh S. Int J Mol Sci. 2022; 12346; 7. Koopman Van Aarsen LA. Cancer Res. 2008: 561-70; 8. Li F. Canc Manag Res. 2020: 9599-9608; 9. Elayadi AN. Cancer Res. 2007: 5889-95; 10. Elez E. Ann Oncol. 2015: 132-40; 11. Burton JK. AAPS J. 2019:12; 12. Lyon RP. SITC 2022: Poster 1186; 13. Trang VH. AACR 2023: Poster 1522; 14. NCT04389632. https://clinicaltrials.gov/study/NCT04389632; Accessed February 25, 2024; 15. NCT06012435. https://clinicaltrials.gov/study/NCT06012435; Accessed February 25, 2024.